Core Insights - Merus N.V. (NASDAQ:MRUS) is highlighted as one of the best biotech stocks to buy, with Barclays initiating coverage and setting a price target of $112 and an Overweight rating [1] - The approval of zenocutuzumab for rare malignancies has validated Merus's platform commercially [1] Group 1: Clinical Developments - Merus's Phase 3 clinical asset, petosemtamab, is undergoing two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers [2] - The clinical derisking of petosemtamab in head and neck malignancies, along with potential value creation in colorectal cancer through year-end 2026, presents a significant opportunity for share gain [2] Group 2: Company Overview - Merus N.V. is a biotechnology company focused on developing antibody-based cancer treatments, with key initiatives including Zenocutuzumab and Petosemtamab (MCLA-158) [3]